Troy Tapped As Top FDA Attorney, Brings WLF Experience To Agency
This article was originally published in The Gray Sheet
Executive Summary
FDA Chief Counsel-designate Daniel Troy is one of the attorneys who successfully challenged the agency's approach to off-label promotion in the WLF suit.
You may also be interested in...
Allen, Azar & Troy: FDA Legal Partners Streamline Enforcement Activity
HHS' decision to elevate FDA warning letter oversight from the Office of Regulatory Affairs to the Office of the Chief Counsel signals an attempt to keep a tighter rein on the agency in the absence of a commissioner
Allen, Azar & Troy: FDA Legal Partners Streamline Enforcement Activity
HHS' decision to elevate FDA warning letter oversight from the Office of Regulatory Affairs to the Office of the Chief Counsel signals an attempt to keep a tighter rein on the agency in the absence of a commissioner
Disclaimers Do Not Remedy Content Violations – FDA Warning Letter
Providing disclaimers for material that promotes an uncleared or unapproved use does not remedy content violations, FDA's device center Promotion and Policy Staff emphasize in a Nov. 5 letter to Diomed